A Florida woman has filed a lawsuit alleging the Type 2 diabetes drug Actos (pioglitazone) caused her to develop bladder cancer. The suit further alleges that the manufacturer, Takeda Pharmaceuticals, knew the risk but failed to disclose it.
According to the complaint, the plaintiff started taking Actos in June 2006 and continued until about January 2010, when she started to suffer from bladder cancer. The U.S. Food and Drug Administration (FDA) has warned about the risks of taking Actos. In 2011, the agency said that taking Actos for more than a year could significantly increase the risk of bladder cancer. The safety label on Actos was updated to address this risk. But lawyers for former Actos users have alleged that Takeda researchers ignored or downplayed concerns about the drug’s cancer-causing potential, delaying years before informing federal regulators of risks uncovered as early as 2004.
Recent research studies provide additional support for a link between Actos and bladder cancer. The British Medical Journal published a study in May 2012 that revealed Actos users were twice as likely to develop bladder cancer after two years on the drug. In July 2012, the Canadian Medical Association Journal reported that patients taking Actos were 22 percent more likely to get bladder cancer.
Parker Waichman LLP filed the suit on July 15, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-2244) as part of a multidistrict Actos litigation (MDL) entitled In Re: Actos (pioglitazone) Products Liability Litigation (6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation.